Most explanations of PSMA therapy eligibility stop at a checklist, and most explanations of side effects stop at a list of percentages. Neither actually answers the two things patients and families want to know once they’re past the basics: where exactly do I fall on this checklist if I’m not a clean yes, and what does the day-to-day of treatment actually feel like. This guide is built around those two gaps, the grey zones in eligibility, and a realistic week-by-week picture of side effects, rather than repeating the general overview you may have already read.
PSMA Therapy: The Quick Eligibility Check
In broad terms, PSMA therapy is considered for men with metastatic castration-resistant prostate cancer whose PSMA PET scan is strongly positive and whose blood counts, kidneys, and liver can tolerate treatment, but the exact thresholds are decided case-by-case, not by a single rule.
- Disease has progressed despite hormone therapy and, usually, at least one line of chemotherapy or an androgen receptor pathway inhibitor
- PSMA PET/CT shows uptake higher than the liver in the metastatic lesions, without significant PSMA-negative disease
- Blood counts, kidney function, and liver function are within a workable range
- Overall functional status allows the patient to manage daily activities largely independently
This checklist filters out the clear no’s and clear yes’s, but in real practice, a meaningful number of patients land somewhere in between, which is the part worth understanding properly.
What Tests Are Needed Before Starting PSMA Therapy?
Before the first cycle, patients need a PSMA PET/CT scan to confirm target expression, plus baseline blood counts, kidney function, and liver function tests.
- PSMA PET/CT scan: confirms the tumour is PSMA-avid and rules out PSMA-negative disease that wouldn’t respond
- Complete blood count (CBC): checks that bone marrow reserve is sufficient to tolerate mild, temporary radiation effects
- Renal function tests (creatinine, eGFR): since the isotope is excreted through the kidneys
- Liver function tests: to rule out significant hepatic impairment
- A clinical review of prior treatments, including chemotherapy and hormonal therapy history
This screening step matters more than it might seem, in the VISION trial, about 1 in 8 patients who were screened did not meet the imaging eligibility criteria simply because their disease no longer expressed enough PSMA. Skipping this step and proceeding on PSA trends alone would mean treating patients who are unlikely to benefit.
Borderline Cases: What Happens If You Tick Some Boxes But Not Others?
A borderline result, slightly low platelets, mixed PSMA uptake, or marginal kidney function, usually means retesting, a short recovery window, or a modified approach, not an automatic rejection.
- Low blood counts after recent chemotherapy: counts often recover within weeks; a repeat blood test 3-4 weeks later can change the answer entirely
- Mixed PSMA-avidity on the scan: some lesions light up strongly while others don’t. Depending on how much disease is PSMA-negative, physicians may still proceed, combine treatments, or consider an alternative such as Actinium-225 PSMA therapy, which has a different targeting profile
- Borderline kidney function: since the therapy is cleared renally, mild impairment doesn’t automatically exclude a patient, but it does change how closely they’re monitored
- Recent radiation to a large bone marrow area (such as prior radium-223 or external beam radiotherapy) can temporarily lower marrow reserve and delay, not necessarily cancel, eligibility
In our experience, “not eligible right now” is one of the most common outcomes at first review, and it is very often followed by “eligible after a short recovery window”, which is why a single scan or lab report should rarely be treated as the final word.
What Are the Common Side Effects of PSMA Therapy?
The most common PSMA therapy side effects, fatigue, dry mouth, and nausea, are usually mild to moderate and temporary, because they occur where healthy tissue also carries small amounts of PSMA.
General pattern based on published radioligand-therapy safety data; your own timeline will be confirmed by your care team.
Long-Term PSMA Therapy Side Effects
Serious (grade 3 or higher) side effects are less common but real, and mainly involve temporary drops in blood counts, which is why regular monitoring is built into every treatment cycle.
- Anaemia: the most common higher-grade effect, seen in around 13% of patients in the VISION trial
- Thrombocytopenia (low platelets): around 8%, usually reversible with monitoring and dose adjustment
- Lymphopenia (low lymphocyte count): around 8%, typically asymptomatic and picked up on routine blood work
- Kidney effects: uncommon, but a reason kidney function is checked before every cycle
To put this in context, grade 3+ adverse events occurred in about 53% of patients receiving Lu-177-PSMA-617 versus 38% on standard care alone in the VISION trial, a difference driven almost entirely by blood-count changes, not organ damage or irreversible harm. This is exactly why every cycle at our Lutetium-177 PSMA therapy programme begins with a fresh blood panel before the next dose is cleared.
PSMA Therapy vs Chemotherapy in Terms of Side Effects
Head-to-head data shows PSMA therapy is generally better tolerated than chemotherapy, with fewer severe side effects for similar or better disease control.
- In the TheraP trial, Lu-177-PSMA-617 was compared directly against cabazitaxel chemotherapy in men with mCRPC
- PSMA therapy showed a longer PSA progression-free survival and a notably lower rate of severe toxicity than chemotherapy
- Hair loss, the classic chemotherapy side effect, does not occur with PSMA therapy
- Since PSMA therapy is given once every six weeks rather than weekly or every three weeks, the cumulative fatigue burden also tends to be lower
For many patients who have already been through one or more lines of chemotherapy, this comparative tolerability is often the most reassuring part of the conversation.
Questions Worth Bringing to Your PSMA Therapy Consultation in Delhi NCR
A short, specific list of questions gets you a far more useful conversation than asking generally “is this treatment safe”, bring these to your nuclear medicine review.
- Does my PSMA PET scan show strong, consistent uptake across my disease sites, or is it mixed?
- Based on my current blood counts, am I eligible now, or would retesting in a few weeks change things?
- How many cycles are realistically being planned for my case, and how will response be checked?
- What specific radiation-safety instructions apply to my household after each infusion?
- If this doesn’t control the disease, what would the next option look like?
Walking in with these five questions turns a passive consultation into an active decision, which, for a treatment this individualised, is exactly how it should be approached.
Conclusion: Making an Informed Decision
Eligibility for PSMA therapy is not a single yes-or-no answer from a lab report, it’s a picture built from imaging, blood work, and treatment history, reviewed together by a nuclear medicine physician. The side-effect profile, meanwhile, is well documented across thousands of trial patients and is generally mild compared with other options available at this stage of disease.
If you’re trying to work out whether this therapy is a realistic next step, the most useful first move is a proper PSMA PET scan and a detailed review with a specialist rather than guessing from PSA numbers alone, you can book a consultation with Dr. Swagat Dash to go through your specific case and reports.
Frequently Asked Questions
Is PSMA therapy a cure for prostate cancer?
No, it is a highly effective disease-control and survival-extending treatment for advanced, PSMA-positive prostate cancer, not a cure, and it’s typically used within a broader long-term treatment plan.
How many cycles of PSMA therapy will I need?
Most protocols use 4 to 6 cycles, spaced six weeks apart, with response assessed through PSA trends and repeat PSMA PET imaging partway through treatment.
Do side effects get worse with each cycle?
Not necessarily, many patients tolerate later cycles similarly to earlier ones, though blood counts are watched closely across the full course since mild cumulative effects can occur.
Where can I get PSMA therapy in Delhi NCR
PSMA therapy (Lutetium-177 and Actinium-225 based) is available at the Centre for Nuclear Medicine & Molecular Theranostics, Sarvodaya Hospital, Faridabad, accredited as North India’s first and India’s third EARL-certified theranostics centre by the European Association of Nuclear Medicine.
Who is the best nuclear medicine specialist in Delhi NCR?
Dr. Swagat Dash, HOD & Senior Consultant of Nuclear Medicine and Molecular Theranostics at Sarvodaya Hospital, Faridabad, is one of the most experienced PSMA-therapy specialists in Delhi NCR, with 17+ years in nuclear medicine.
Sources:
- Sartor O, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM, 2021 (VISION trial).
- Hofman MS, et al. 177Lu-PSMA-617 versus cabazitaxel (TheraP trial). Lancet, 2021.
- Kessel K, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy. EJNMMI Research, 2021.
- Kendi AT, et al. Feasibility of 177Lu-PSMA Administration as Outpatient Procedure. Journal of Nuclear Medicine, 2024.
- Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy, PMC, 2024.
